Logo image of NGMD.CA

NUGEN MEDICAL DEVICES INC (NGMD.CA) Stock Fundamental Analysis

TSX-V:NGMD - TSX Venture Exchange - CA67054F1009 - Common Stock - Currency: CAD

0.055  0 (0%)

Fundamental Rating

1

We assign a fundamental rating of 1 out of 10 to NGMD. NGMD was compared to 0 industry peers in the Unkown industry. NGMD may be in some trouble as it scores bad on both profitability and health. While showing a medium growth rate, NGMD is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year NGMD has reported negative net income.
In the past year NGMD has reported a negative cash flow from operations.
NGMD.CA Yearly Net Income VS EBIT VS OCF VS FCFNGMD.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 2024 -2M -4M -6M -8M

1.2 Ratios

Industry RankSector Rank
ROA -40.2%
ROE N/A
ROIC N/A
ROA(3y)-85.48%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
NGMD.CA Yearly ROA, ROE, ROICNGMD.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 2024 0 200 -200 400 -400

1.3 Margins

In the last couple of years the Gross Margin of NGMD has declined.
NGMD does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 51.68%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-8.27%
GM growth 5YN/A
NGMD.CA Yearly Profit, Operating, Gross MarginsNGMD.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023 2024 0 -1K -2K -3K -4K -5K

More info and screens

2

2. Health

2.1 Basic Checks

NGMD does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for NGMD has been increased compared to 1 year ago.
Compared to 1 year ago, NGMD has a worse debt to assets ratio.
NGMD.CA Yearly Shares OutstandingNGMD.CA Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 2024 50M 100M 150M 200M
NGMD.CA Yearly Total Debt VS Total AssetsNGMD.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 2024 5M 10M 15M

2.2 Solvency

NGMD has an Altman-Z score of -3.36. This is a bad value and indicates that NGMD is not financially healthy and even has some risk of bankruptcy.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -3.36
ROIC/WACCN/A
WACC6.26%
NGMD.CA Yearly LT Debt VS Equity VS FCFNGMD.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 2024 0 5M -5M 10M 15M

2.3 Liquidity

NGMD has a Current Ratio of 5.82. This indicates that NGMD is financially healthy and has no problem in meeting its short term obligations.
NGMD has a Quick Ratio of 5.58. This indicates that NGMD is financially healthy and has no problem in meeting its short term obligations.
Industry RankSector Rank
Current Ratio 5.82
Quick Ratio 5.58
NGMD.CA Yearly Current Assets VS Current LiabilitesNGMD.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 2024 2M 4M 6M

More info and screens

4

3. Growth

3.1 Past

NGMD shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 81.97%, which is quite impressive.
The Revenue has grown by 204.49% in the past year. This is a very strong growth!
NGMD shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 94.29% yearly.
EPS 1Y (TTM)81.97%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%177.53%
Revenue 1Y (TTM)204.49%
Revenue growth 3Y94.29%
Revenue growth 5YN/A
Sales Q2Q%146.62%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
NGMD.CA Yearly Revenue VS EstimatesNGMD.CA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 2024 200K 400K 600K 800K 1M

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for NGMD. In the last year negative earnings were reported.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NGMD.CA Price Earnings VS Forward Price EarningsNGMD.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NGMD.CA Per share dataNGMD.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.01 -0.02 -0.03 -0.04

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for NGMD!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

NUGEN MEDICAL DEVICES INC

TSX-V:NGMD (6/30/2025, 7:00:00 PM)

0.055

0 (0%)

Chartmill FA Rating
GICS SectorN/A
GICS IndustryGroupN/A
GICS IndustryN/A
Earnings (Last)06-03 2025-06-03
Earnings (Next)08-27 2025-08-27
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners6.57%
Ins Owner ChangeN/A
Market Cap12.49M
AnalystsN/A
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 12.36
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.01
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.02
FCFYN/A
OCF(TTM)-0.02
OCFYN/A
SpS0
BVpS-0.03
TBVpS-0.05
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -40.2%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 51.68%
FCFM N/A
ROA(3y)-85.48%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-8.27%
GM growth 5YN/A
F-Score5
Asset Turnover0.08
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 1.61%
Cap/Sales 1.03%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.82
Quick Ratio 5.58
Altman-Z -3.36
F-Score5
WACC6.26%
ROIC/WACCN/A
Cap/Depr(3y)0.73%
Cap/Depr(5y)N/A
Cap/Sales(3y)0.86%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)81.97%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%177.53%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)204.49%
Revenue growth 3Y94.29%
Revenue growth 5YN/A
Sales Q2Q%146.62%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y35.92%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y29.67%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y29.79%
OCF growth 3YN/A
OCF growth 5YN/A